Abstract
Background Chronic cough is a symptom of common lung conditions, occurs as a side effect of ACE inhibitors (ACEis), or may be unexplained. Despite chronic cough representing a substantial health burden, its biological mechanisms remain unclear. We hypothesised shared genetic architecture between chronic dry cough and ACEi-induced cough and aimed to identify causal genes underlying both phenotypes.
Methods We performed multi-ancestry genome-wide association studies (GWAS) of chronic dry cough and ACEi-induced cough, and a multi-trait GWAS of both phenotypes, utilising data from five cohort studies. Chronic dry cough was defined by questionnaire responses, and ACEi-induced cough by treatment switches or clinical diagnosis in electronic health records. We mapped putative causal genes and performed phenome-wide association studies (PheWAS) of associated variants and genetic risk scores (GRS) for these phenotypes to identify pleotropic effects.
Findings We found seven novel genetic association signals reaching p-value <5×10−8 in the multi-trait or single-trait analyses of chronic dry cough and ACEi-induced cough. The novel variants mapped to 10 novel genes, and we mapped an additional three novel genes to known risk variants, many of which implicating neurological functions (CTNNA1, KCNA10, MAPKAP1, OR4C12, OR4C13, SIL1). The GRS-PheWAS highlighted associations with increased risk of several conditions reported as comorbidities of chronic cough, including fibromyalgia pain, and with spirometry measurements.
Interpretation Our findings advance the understanding of neuronal dysfunction underlying cough hypersensitivity in chronic dry cough and ACEi-induced cough at the population-level, and the identification of comorbidities associated with genetic predisposition to cough could inform drug target discovery.
Funding Medical Research Council, Wellcome Trust, National Institute for Health and Care Research, Orion Pharma.
Evidence before this study We searched the National Human Genome Research Institute-European Bioinformatic Institute Catalog of human genome-wide association studies (GWAS) from inception through to 21st May 2024, using the search term “cough” to identify publications which tested association between genetic variants and cough. Additionally, we searched PubMed for English language articles published before 21st May 2024 using the terms “cough” or “ACE inhibitor” combined with “genome-wide association” to find relevant publications. We manually filtered the results from both searches to ensure the cough-related publications related to a dry, unproductive cough. To date, there have been no GWAS of unexplained dry cough, while several for ACE inhibitor (ACEi)-induced cough have identified 11 associated genetic loci at genome-wide significance (p-value <5×10−8). These loci have implicated genes involved in neuronal excitability and the bradykinin pathway.
Added value of this study We present the first multi-ancestry GWAS of chronic dry cough, defined using questionnaire responses, and the largest multi-ancestry GWAS of ACEi-induced cough, characterised by either a medication switch from an ACEi to an angiotensin-II receptor blocker or a clinical diagnosis. By leveraging the clinical and genetic overlap between these two traits, we conducted a multi-trait GWAS to identify novel associated loci. Across the multi-trait and single-trait analyses, we identified seven novel associated loci at genome-wide significance (p-value <5×10−8), mapped to 10 genes which have not previously been linked to cough phenotypes.
Implications of all the available evidence We identified novel genes involved in neurological processes (CTNNA1, KCNA10, OR4C12, OR4C13) or implicated in neurological or neurodegenerative conditions (SIL1 and MAPKAP1). The genes we implicate from all genetic associations with cough to date support the role of neurobiological processes underlying dry cough biology, and highlight potential therapeutic targets.
Competing Interest Statement
CJ, RP, LVW and MDT report funding from Orion Pharma within the scope of the submitted work. LVW has held research grants from GlaxoSmithKline (as principal investigator) unrelated to current work, and reports consultancy for Galapagos. WH and MM are salaried employees of Orion Pharma. MDT has research collaborations with GlaxoSmithKline unrelated to the current work. CE has received unrestricted research grants from Novo Nordisk and Abbott Diagnostics; no personal fees.
Funding Statement
This study was supported by the following: UKRI (MRC) Innovation Fellowship at Health Data Research UK grant number MR/S003762/1 to CB; Wellcome Trust Investigator Award (WT202849/Z/16/Z); Wellcome Trust Discovery Award (WT225221/Z/22/Z), NIHR Senior Investigator Award (NIHR201371) to MDT and the NIHR Leicester Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. EFM is funded by Barts Charity and Barts NIHR BRC. Orion Pharma supported this work through a funded research collaboration with the University of Leicester, through which DeepPheWAS was developed. We used DeepPheWAS for the PheWAS analyses presented in this paper and co-authors William Hennah and Mikko Marttila are salaried employees of Orion Pharma.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank genetic and phenotypic data were obtained under UK Biobank applications 43027 and 59822. UK Biobank has ethical approval from the UK National Health Service (NHS) National Research Ethics Service (11/NW/0382). EXCEED received ethical approval from the Leicester Central Research Ethics Committee (13/EM/0226), and substantial amendments have been approved by the same Research Ethics Committee for the collection of new data relating to the COVID-19 pandemic, including the COVID-19 questionnaires and antibody testing. Genes & Health operates under ethical approval, 14/LO/1240, from London South East NRES Committee of the Health Research Authority, dated 16 September 2014. The establishment of Copenhagen Hospital Biobank was approved by the Danish Data Protection Agency (file number 2007-580015; institutional file number RH2007-30-4129/ I-suite 00678).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Access to UK Biobank (https://www.ukbiobank.ac.uk), EXCEED (https://exceed.org.uk/), Genes & Health (https://www.genesandhealth.org/) and Copenhagen Hospital Biobank individual-level data are available to approved researchers upon application or data access request. Genome-wide summary statistics from the single-trait and multi-trait analyses will be made publicly available via the EMBL-EBI GWAS Catalog. The ACEi-induced cough phenotyping algorithm is publicly available (https://doi.org/10.5281/zenodo.6780065), and scripts used to run additional analyses are available upon request.
